Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPα-p300 Axis

Citations Over TimeTop 10% of 2018 papers

Abstract

The aging liver is affected by several disorders, including steatosis, that can lead to a decline of liver functions. Here, we present evidence that the cdk4-C/EBPα-p300 axis is a critical regulator of age-associated disorders, including steatosis. We found that patients with non-alcoholic fatty liver disease (NAFLD) have increased levels of cdk4 and that cdk4-resistant C/EBPα-S193A mice do not develop hepatic steatosis with advancing age. Underlying mechanisms include a block in C/EBPα activation and subsequent failure in activation of enzymes involved in the development of NAFLD. Inhibition of cdk4 in aged wild-type (WT) mice by a specific cdk4 inhibitor, PD-0332991, reduces C/EBPα-p300 complexes and eliminates hepatic steatosis. Moreover, the inhibition of cdk4 in aged mice reverses many age-related disorders. Mechanisms of correction include elimination of cellular senescence and alterations in the chromatin structure of hepatocytes. Thus, the inhibition of cdk4 might be considered as a therapeutic approach to correct age-associated liver disorders.

Related Papers

• → Hepatitis C Virus-Induced Hepatocellular Steatosis(2005)78 cited
• → Fluorescence spectroscopy to diagnose hepatic steatosis in a rat model of fatty liver(2009)19 cited
• → Rapid Decrease in Liver Graft Steatosis in the Early Post-transplant Period: A Blinded and Randomized Study(2019)3 cited
• → Regression of Graft Steatosis After Liver Transplantation(2022)1 cited
• [Steatosis in chronic viral hepatitis C: frequency, risk factors and relationship with fibrosis].(2008)